Companies › IBIO
iBio Inc (IBIO)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001420720 · EDGAR filings · Updated 2026-07-17
iBio Inc (IBIO) has reported institutional ownership of 39.1%, with 52 institutional managers holding positions valued at $36.9M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-17 — Current report (8-K) filed
- 2026-07-01 — Current report (8-K) filed
- 2026-05-19 — Insider transaction reported (Form 4)
- 2026-05-15 — SCHEDULE 13G/A filed
- 2026-05-15 — SCHEDULE 13G/A filed
- 2026-05-15 — SCHEDULE 13G/A filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, iBio Inc has 52 institutional holders and institutional ownership of 39.1%.
Insider activity
Insiders reported 4 transactions (4 buys, 0 sells) across 3 reporting insiders, with a net reported value of $98.1K.
Data flags from SEC filings
Related companies
Cardiol Therapeutics Inc (CRDL) · BIOMEA FUSION INC (BMEA) · INSPIREMD INC (NSPR) · PROTALIX BIOTHERAPEUTICS INC (PLX) · SEER INC (SEER) · HUMACYTE INC (HUMA)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.